Previous Article | Next Article ![]()
Infection and Immunity, April 2001, p. 2031-2036, Vol. 69, No. 4
Toxinology and Aerobiology Division, United
States Army Medical Research Institute of Infectious Diseases, Fort
Detrick, Maryland 21702-5011
Received 25 September 2000/Returned for modification 14 December
2000/Accepted 3 January 2001
Previous work in our laboratory revealed that mice parenterally
vaccinated with recombinantly attenuated staphylococcal enterotoxin (SE) or toxic shock syndrome toxin 1 develop protective antibodies against a lethal intraperitoneal (i.p.) toxin challenge. This study
investigated the efficacy of nasal and oral immunizations with an SEB
vaccine (SEBv) toward an i.p. or mucosal (via an aerosol) toxin
challenge. Both vaccination routes, with the immunoadjuvant cholera
toxin (CT), elicited comparable SEB-specific immunoglobulin A (IgA) and
IgG levels in saliva. Nasal or oral inoculations also generated
SEB-specific IgA, IgG, and IgM in the serum, but the nasal route
yielded higher specific IgG titers. SEBv alone, when given nasally or
orally, did not induce any detectable SEB-specific antibody. Mice
vaccinated mucosally were protected against a 50% lethal dose of
wild-type SEB given i.p. or mucosally, thus demonstrating that nasal or
oral administration of this SEBv, with CT, elicits systemic and mucosal
antibodies to SEB that protect against SEB-induced lethal shock.
0019-9567/01/$04.00+0 DOI: 10.1128/IAI.69.4.2031-2036.2001
Mucosal Vaccination with Recombinantly Attenuated
Staphylococcal Enterotoxin B and Protection in a Murine Model
*
Corresponding author. Mailing address: Toxinology and
Aerobiology Division, Department of Immunology and Molecular Biology, USAMRIID, Fort Detrick, MD 21702-5011. Phone: (301) 619-4809. Fax:
(301) 619-2348. E-mail:
bradley.stiles{at}amedd.army.mil.
This article has been cited by other articles:
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»